SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

VONVENDI

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market since 2015 (US) and 2018 (EU). The latest expanded indication was approved in September 2025 (US) and July 2026 (EU pediatric).
Why 4/10
No hard binary catalyst (PDUFA / pivotal readout) is scheduled for VONVENDI in the next 12 months; it is an already-approved, marketed product. The drug is a minor contributor to Takeda (a large diversified pharma with ~JPY 4.5 trillion revenue), so even the expanded September 2025 approval was not a company-level binary event.
Actionable Insight NEUTRAL

With VONVENDI's expanded FDA approval already secured (September 2025) and no pending PDUFA or pivotal readout on the horizon, the stock-moving catalyst for Takeda related to this drug has passed. Watch Takeda's quarterly earnings (next: H1 FY2026, reported October 29, 2026) for VONVENDI sales growth as a signal of commercial execution under the expanded label, but this single product is too small to drive Takeda's share price directionally.

Price Chart

Loading chart...

Executive Summary

VONVENDI (vonicog alfa / recombinant von Willebrand factor) is Takeda's approved treatment for von Willebrand disease, the most common inherited bleeding disorder. First approved in 2015 for on-demand adult use, its label was significantly expanded in September 2025 to cover routine prophylaxis for adults with all VWD types and on-demand/perioperative use in children. VONVENDI is the only recombinant (non-plasma-derived) VWF therapy on the market, differentiating it from older plasma-derived products like Humate-P. Sales reached JPY 16.2 billion (~$108M) in FY2025, growing 32.5% year-over-year, driven by the expanded indication. However, VONVENDI represents a tiny fraction of Takeda's overall revenue (~0.4%), and no upcoming binary catalysts exist for this drug.

How It Works

VONVENDI is a lab-made (recombinant) copy of von Willebrand factor, a protein the body needs for normal blood clotting. People with von Willebrand disease (VWD) are born deficient or lacking this protein, so they bruise and bleed easily. VONVENDI replaces the missing protein, restoring the blood's ability to clot and stopping or preventing bleeding episodes.

Trial Status

VONVENDI was initially FDA-approved in 2015 for on-demand treatment of bleeding episodes in adults based on Phase 3 data. A supplemental BLA expanded approval in 2022 for prophylaxis in adults with severe Type 3 VWD. In September 2025, FDA approved a major label expansion to include routine prophylaxis for adults with all VWD types (1, 2 and 3) plus on-demand and perioperative use in pediatric patients, supported by additional Phase 3 and Phase 3b studies. The EU counterpart, Veyvondi, received pediatric approval from EMA in 2026.

The Two-Sided Case

▲ Bull Case1
VONVENDI is the only recombinant (non-plasma-derived) von Willebrand factor therapy approved in the US, avoiding the theoretical pathogen risk associated with human plasma-derived products. The September 2025 FDA expansion dramatically broadened the addressable population to all adult VWD types (1, 2 and 3) plus pediatric patients, representing a major market expansion. Sales grew 32.5% YoY to JPY 16.2 billion in FY2025, driven by expanded indications and increased US demand. The EU counterpart Veyvondi received pediatric approval in 2026, opening another growth avenue. Takeda holds orphan drug exclusivity, and the VWD treatment market is projected to reach ~$1 billion by 2032-2035.
▼ Bear Case1
VONVENDI is a tiny product within Takeda's massive portfolio (~JPY 16B of JPY ~4.5T total revenue, roughly 0.4%), so even strong sales growth has negligible impact on Takeda's stock. The VWD therapeutic market is relatively small (~$580 million in 2025), limiting peak revenue potential. VONVENDI faces entrenched competition from established plasma-derived products (CSL Behring's Humate-P, Octapharma's Wilate), which have decades of clinical data and physician familiarity. There are no upcoming binary catalysts (PDUFA dates, pivotal readouts) for this drug, making it a slow commercial story with no event-driven upside for the stock. Competitors are also expanding into pediatrics, narrowing VONVENDI's differentiation.

Upcoming Catalysts

  • None scheduled for VONVENDI specifically; it is an approved, marketed drug with no pending PDUFA dates or pivotal readouts. Takeda's next relevant catalyst would be quarterly earnings reports where VONVENDI sales growth trajectory is disclosed.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 businesswire.com3 takeda.com4 fda.gov5 takeda.com6 publicnow.com7 en.wikipedia.org8 ema.europa.eu9 bioplayground.com10 expertmarketresearch.com